Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)

被引：0

作者：

Yap, Y. S. ^{[1
]}

Su, F. ^{[2
]}

Joshi, M. ^{[3
]}

Chiu, J. ^{[4
]}

Masuda, N.

Ito, Y. ^{[5
]}

Ishikawa, T. ^{[6
]}

Aruga, T. ^{[7
]}

Kim, S. J. ^{[8
]}

Deore, U. ^{[2
]}

Babbar, N. ^{[2
]}

Balbin, A. ^{[3
]}

机构：

[1] NCCS Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore

[2] Novartis Pharmaceut, Oncol, E Hanover, NJ USA

[3] Novartis Inst BioMed Res, Oncol, Cambridge, MA USA

[4] Queen Mary Hosp, Oncol, Hong Kong, Peoples R China

[5] Canc Inst Hosp JFCR, Oncol, Tokyo, Japan

[6] Tokyo Med Univ Hosp, Oncol, Tokyo, Japan

[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Breast Surg, Tokyo, Japan

[8] Osaka Univ Hosp, Oncol, Osaka, Japan

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.515

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

232P

引用

页码：S459 / S460

页数：2